Taking Aim at ‘Dark’ Genome to Uncover New Therapies for Disease
In an attempt to fulfill the lofty ambitions of the original Human Genome Project, Duke University engineers, scientists and physicians are joining forces in a new initiative to develop the missing technologies needed to understand…
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary orphan diseases, today announced the completion of its Phase 2a clinical trial of PB2452. Full data…
New CRISPR class expands genetic engineering toolbox
Biomedical engineers at Duke University have used a previously unexplored CRISPR technology to accurately regulate and edit genomes in human cells. With this new approach, the researchers hope to dramatically expand the CRISPR-based tools available to biomedical…
Exclusive License Agreement for Duke start-up, restor3D®
Ken Gall’s 3D-printing company, restor3D, has signed an exclusive license with SeaSpine, a global medical tech company. SeaSpine Holdings Corporation (SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal…
Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational…
Duke biomedical engineers utilize ML to improve medical scan imagery
Biomedical engineers at Duke University have devised a method for increasing the resolution of optical coherence tomography (OCT) down to a single micrometer in all directions, even in a living patient. The new technique, called…
PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the receipt of written minutes from the End-of-Phase 1 meeting with the U.S.…
Researchers Are Using Machine Learning to Screen for Autism in Children
Parents and doctors face a difficult dilemma when it comes to detecting and treating autism spectrum disorder (ASD) in children. It’s critically important to diagnose ASD as early in a child’s development as possible. Starting treatment…
Top 10 Companies Leveraging Gene Editing in 2019
Bayer made much of its desire to establish a cell therapy pipeline on August 8 when it announced it would shell out up to $600 million to acquire full control of BlueRock Therapeutics. But the…